MX370897B - Compuestos bicíclicos fusionados para el tratamiento de enfermedades, - Google Patents

Compuestos bicíclicos fusionados para el tratamiento de enfermedades,

Info

Publication number
MX370897B
MX370897B MX2017012342A MX2017012342A MX370897B MX 370897 B MX370897 B MX 370897B MX 2017012342 A MX2017012342 A MX 2017012342A MX 2017012342 A MX2017012342 A MX 2017012342A MX 370897 B MX370897 B MX 370897B
Authority
MX
Mexico
Prior art keywords
disease
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
MX2017012342A
Other languages
English (en)
Other versions
MX2017012342A (es
Inventor
Benjamin Anthony Pratt
Raju Mohan
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of MX2017012342A publication Critical patent/MX2017012342A/es
Publication of MX370897B publication Critical patent/MX370897B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos bicíclicos fusionados, composiciones y método para uso para el tratamiento de enfermedades.
MX2017012342A 2015-03-26 2016-03-25 Compuestos bicíclicos fusionados para el tratamiento de enfermedades, MX370897B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Publications (2)

Publication Number Publication Date
MX2017012342A MX2017012342A (es) 2018-06-11
MX370897B true MX370897B (es) 2020-01-09

Family

ID=56072361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012342A MX370897B (es) 2015-03-26 2016-03-25 Compuestos bicíclicos fusionados para el tratamiento de enfermedades,

Country Status (16)

Country Link
US (4) US10421759B2 (es)
EP (2) EP3274350A1 (es)
JP (1) JP6843061B2 (es)
KR (1) KR20180003545A (es)
CN (1) CN107912042A (es)
AU (2) AU2016238523A1 (es)
BR (1) BR112017020374A2 (es)
CA (1) CA2980394A1 (es)
CL (1) CL2017002405A1 (es)
CO (1) CO2017010621A2 (es)
HK (1) HK1249756A1 (es)
IL (1) IL254572A0 (es)
MX (1) MX370897B (es)
RU (2) RU2017137366A (es)
SG (2) SG10201908881PA (es)
WO (1) WO2016151403A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201908881PA (en) * 2015-03-26 2019-11-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
KR20190040936A (ko) * 2016-05-25 2019-04-19 아카나 테라퓨틱스, 엘티디. 파르네소이드 x 수용체 (fxr) 조정제와의 조합 요법
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． 疾患治療用の縮合二環式化合物
TW201910332A (zh) * 2017-06-02 2019-03-16 英商艾卡那治療有限公司 稠合的雙環化合物
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
AU2005272916A1 (en) 2004-08-10 2006-02-23 Exelixis, Inc. Heterocyclic compounds as pharmaceutical agents
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
CA2633243C (en) * 2005-12-15 2014-05-27 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090131409A1 (en) 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
SG11201703953WA (en) * 2014-11-21 2017-06-29 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
KR20170117030A (ko) * 2014-12-22 2017-10-20 아카나 테라퓨틱스, 엘티디. 질환의 치료를 위한 융합된 비시클릭 화합물
SG10201908881PA (en) * 2015-03-26 2019-11-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
SG11201707610PA (en) 2017-10-30
JP2018510876A (ja) 2018-04-19
HK1249756A1 (zh) 2018-11-09
KR20180003545A (ko) 2018-01-09
CL2017002405A1 (es) 2018-04-27
BR112017020374A2 (pt) 2018-06-05
US20210214362A1 (en) 2021-07-15
AU2016238523A1 (en) 2017-11-09
RU2017137366A3 (es) 2019-07-17
WO2016151403A1 (en) 2016-09-29
AU2020256301A1 (en) 2020-11-05
MX2017012342A (es) 2018-06-11
CN107912042A (zh) 2018-04-13
CA2980394A1 (en) 2016-09-29
US10421759B2 (en) 2019-09-24
RU2021107054A (ru) 2021-03-31
JP6843061B2 (ja) 2021-03-17
IL254572A0 (en) 2017-11-30
EP3715348A1 (en) 2020-09-30
US20180118752A1 (en) 2018-05-03
US20230002394A1 (en) 2023-01-05
US20200079782A1 (en) 2020-03-12
CO2017010621A2 (es) 2018-01-31
RU2017137366A (ru) 2019-04-26
SG10201908881PA (en) 2019-11-28
EP3274350A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
ZA202004557B (en) Modulatory polynucleotides
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12019501079A1 (en) Magl inhibitors
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
MY184870A (en) Immunomodulators
MD20170032A2 (ro) Anticorpi anti-TIGIT
PH12016501763B1 (en) Multispecific antibodies
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
PT3580211T (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro

Legal Events

Date Code Title Description
FG Grant or registration